Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-061222
Filing Date
2025-04-30
Accepted
2025-04-30 17:06:58
Documents
57
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q lrmr-20250331.htm   iXBRL 10-Q 1604510
2 EX-31.1 lrmr-ex31_1.htm EX-31.1 11535
3 EX-31.2 lrmr-ex31_2.htm EX-31.2 11649
4 EX-32.1 lrmr-ex32_1.htm EX-32.1 20725
  Complete submission text file 0000950170-25-061222.txt   7701365

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20250331.xsd EX-101.SCH 997294
60 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20250331_htm.xml XML 1508544
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 25896761
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)